This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (17)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Effect of Probenecid on Monoamine Catabolite Levels in Cerebrospinal Fluid

Thomas N. Chase, MD; James A. Schnur, MD; Jacob A. Brody, MD; Edna K. Gordon

Arch Neurol. 1971;25(1):9-13.

Abstract
Changes in cerebrospinal fluid (CSF) levels of homovanillic acid (HVA), a major catabolite of dopamine and of 5-hydroxyindoleacetic acid (5-HIAA), the principle product of serotonin degradation, were compared in Guamanian parkinsonism-dementia (PD) and amyotrophic lateral sclerosis (ALS) patients with Guamanian and North American control subjects during the administration of probenecid. The rise of both HVA and 5-HIAA was significantly less in PD patients than in control subjects. Values for both these monoamine catabolites in patients with ALS consistently fell between those of PD patients and controls. Since probenecid inhibits the efflux of HVA and 5-HIAA from CSF, these results suggest that a substantial reduction in the synthesis of both dopamine and serotonin may attend PD and ALS of Guam.

Author Affiliations
Bethesda, Md

From the Laboratory of Clinical Science (Dr. Chase and Mrs. Gordon), National Institute of Mental Health, and the Epidemiology Branch (Drs. Schnur and Brody), National Institute of Neurologic Diseases and Stroke, Bethesda, Md.

Footnotes
Accepted for publication Jan 7, 1971.

Reprint requests to Section on Experimental Therapeutics, National Institute of Mental Health, Bethesda, Md 20014 (Dr. Chase).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

CSF Monoamine Metabolites in Child and Adult Psychiatric Patients: A Developmental Perspective
Leckman et al.
Arch Gen Psychiatry 1980;37:677-681.
 

Inosiplex and Amyotrophic Lateral Sclerosis: Therapeutic Trial in Patients on Guam
Brody et al.
Arch Neurol 1974;30:322-323.
ABSTRACT  

Amyotrophic Lateral Sclerosis: A Study of Central Monoamine Metabolism and Therapeutic Trial of Levodopa
Mendell et al.
Arch Neurol 1971;25:320-325.
ABSTRACT